Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention

World Journal of Clinical Oncology

Volumn 6, Issue 5, 2015, Pages 133-141

  Pabla, Baldeep ^a   Bissonnette, Marc ^a   Konda, Vani J ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Colon cancer; Curcumin; Epidermal growth factor receptor; Ginseng; Green tea; Western diet

Indexed keywords

EID: 84945136638     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i5.133     Document Type: Review

References (77)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]
2. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003; 2: 246-251 [PMID: 12620146 DOI: 10.3816/CCC.2003.n.006]
3. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783-5788 [PMID: 18809606 DOI: 10.1200/JCO.2008.17.5950]
4. Bülow S, Faurschou Nielsen T, Bülow C, Bisgaard ML, Karlsen L, Moesgaard F. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int J Colorectal Dis 1996; 11: 88-91 [PMID: 8739833 DOI: 10.1007/BF00342466]
5. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, Negri E, Straif K, Romieu I, La Vecchia C, Boffetta P, Jenab M. Alcohol drinking and colorectal cancer risk: an overall and doseresponse meta-analysis of published studies. Ann Oncol 2011; 22: 1958-1972 [PMID: 21307158 DOI: 10.1093/annonc/mdq653]
6. Henderson TO, Oeffinger KC, Whitton J, Leisenring W, Neglia J, Meadows A, Crotty C, Rubin DT, Diller L, Inskip P, Smith SA, Stovall M, Constine LS, Hammond S, Armstrong GT, Robison LL, Nathan PC. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012; 156: 757-766, W-260 [PMID: 22665813 DOI: 10.7326/0003-4819-156-11-201206 050-00002]
7. Dougherty U, Cerasi D, Taylor I, Kocherginsky M, Tekin U, Badal S, Aluri L, Sehdev A, Cerda S, Mustafi R, Delgado J, Joseph L, Zhu H, Hart J, Threadgill D, Fichera A, Bissonnette M. Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Clin Cancer Res 2009; 15: 6780-6789 [PMID: 19903783 DOI: 10.1158/1078-0432. CCR-09-1678]
8. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300: 2765-2778 [PMID: 19088354 DOI: 10.1001/ jama.2008.839]
9. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-662 [PMID: 1736104 DOI: 10.1056/NEJM199203053261 002]
10. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104: 739-750 [PMID: 19240699 DOI: 10.1038/ajg.2009.1 04]
11. Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V, Hommes DW, Shedlovsky A, Dove WF, van den Brink GR. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci USA 2014; 111: 16514-16519 [PMID: 25368192 DOI: 10.1073/pnas.1323064111]
12. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
13. Fensterheim R. Colon cancer. NCCN Guidelines. Availbale from: URL: http://www.nccn.org/about/nhl.pdf
14. Czito BG, Bendell J, Willett CG. Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era? Oncology (Williston Park) 2006; 20: 179-187; discussion 187-188, 192 [PMID: 16562650]
15. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643 [PMID: 10404636 DOI: 10.1016/S1357-2725(99)00015-1]
16. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-779 [PMID: 14993236 DOI: 10.1083/jcb.200307137]
17. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32S-40S [PMID: 11560969 DOI: 10.3978/j.issn.2218-6751.2014.05.01]
18. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998; 184: 53-57 [PMID: 9582527 DOI: 10.1002/(S ICI)1096-9896(199801)184: 1<53: : AID-PATH6>3.0.CO; 2-7]
19. Grotendorst GR, Soma Y, Takehara K, Charette M. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989; 139: 617-623 [PMID: 2786881 DOI: 10.1002/ jcp.1041390323]
20. Gille J, Swerlick RA, Caughman SW. Transforming growth factoralpha- induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997; 16: 750-759 [PMID: 9049304 DOI: 10.1093/emboj/16.4.750]
21. Sastry KS, Karpova Y, Kulik G. Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 2006; 281: 27367-27377 [PMID: 16847055 DOI: 10.1074/jbc. M511485200]
22. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70: 722-726 [PMID: 9096655 DOI: 10.1002/(SICI)1097-0215(19970317)70: 6<722: : AID-IJC15>3.0.CO; 2-B]
23. Zhu H, Dougherty U, Robinson V, Mustafi R, Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A, Joseph L, Bissonnette M. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res 2011; 9: 960-975 [PMID: 21653642 DOI: 10.1158/1541-7786.MCR-10-0531]
24. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43-68 [PMID: 5635018]
25. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004; 95: 475-480 [PMID: 15182426 DOI: 10.1111/j.1349-7006.2004.tb03235.x]
26. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007; 67: 827-835 [PMID: 17234795 DOI: 10.1158/0008-5472.CAN-05-3343]
27. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, Cohen EE, Aluri L, Fichera A, Bissonnette M. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008; 14: 2253-2262 [PMID: 18413814 DOI: 10.1158/1078-0432.CCR-07-4926]
28. Dougherty U, Mustafi R, Valuckaite V, Konda VJ, Pekow J, Sadiq F, Haider HI, Adhikari S, Hart J, Joseph L, Li YC, Bissonnette M. Western diet up-regulates ADAM17, a key meditator of EGFR signaling via activation of colonic renin-angiotensin system and inhibition of miR-145, -148a and -152. Gastroenterology 2015; 148: S-99 [DOI: 10.1016/S0016-5085(15)30338-3]
29. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005; 207: 156-163 [PMID: 16041691 DOI: 10.1002/path.1814]
30. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883 [PMID: 15625347 DOI: 10.1056/ NEJM200412303512724]
31. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512 [PMID: 9727977 DOI: 10.1126/science.281.5382.1509]
32. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63: 728-734 [PMID: 12566320]
33. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426 [PMID: 10201372 DOI: 10.1038/18884]
34. Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 2008; 283: 12686-12690 [PMID: 18356165 DOI: 10.1074/jbc.C700185200]
35. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 2005; 39: 98-109 [PMID: 15681903]
36. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
37. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9: 748-760 [PMID: 19754359 DOI: 10.2174/15 6800909789271495]
38. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. The gut microbiome modulates colon tumorigenesis. MBio 2013; 4: e00692-e00613 [PMID: 24194538 DOI: 10.1128/mBio.00692-13]
39. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev 1995; 4: 401-408 [PMID: 7655337]
40. Yun TK, Zheng S, Choi SY, Cai SR, Lee YS, Liu XY, Cho KJ, Park KY. Non-organ-specific preventive effect of long-term administration of Korean red ginseng extract on incidence of human cancers. J Med Food 2010; 13: 489-494 [PMID: 20521975 DOI: 10.1089/jmf.2009.1275]
41. Yun TK, Choi SY. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int J Epidemiol 1998; 27: 359-364 [PMID: 9698120 DOI: 10.1093/ije/27.3.359]
42. Yun TK. Experimental and epidemiological evidence on nonorgan specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res 2003; 523-524: 63-74 [PMID: 12628504 DOI: 10.1016/S0027-5107(02)00322-6]
43. Qi LW, Wang CZ, Yuan CS. American ginseng: potential structurefunction relationship in cancer chemoprevention. Biochem Pharmacol 2010; 80: 947-954 [PMID: 20599804 DOI: 10.1016/ j.bcp.2010.06.023]
44. Yun TK, Lee YS, Lee YH, Kim SI, Yun HY. Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds. J Korean Med Sci 2001; 16 Suppl: S6-18 [PMID: 11748383]
45. Han HJ, Yoon BC, Lee SH, Park SH, Park JY, Oh YJ, Lee YJ. Ginsenosides inhibit EGF-induced proliferation of renal proximal tubule cells via decrease of c-fos and c-jun gene expression in vitro. Planta Med 2002; 68: 971-974 [PMID: 12451485 DOI: 10.1055/ s-2002-35659]
46. Cui X, Jin Y, Poudyal D, Chumanevich AA, Davis T, Windust A, Hofseth A, Wu W, Habiger J, Pena E, Wood P, Nagarkatti M, Nagarkatti PS, Hofseth L. Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis 2010; 31: 1734-1741 [PMID: 20729391 DOI: 10.1093/carcin/bgq163]
47. Dougherty U, Mustafi R, Wang Y, Musch MW, Wang CZ, Konda VJ, Kulkarni A, Hart J, Dawson G, Kim KE, Yuan CS, Chang EB, Bissonnette M. American ginseng suppresses Western dietpromoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med 2011; 11: 111 [PMID: 22070864 DOI: 10.1186/1472-6882-11-111]
48. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin- 3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2004; 279: 12755-12762 [PMID: 14701854 DOI: 10.1074/jbc.M312333200]
49. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395 [PMID: 11882383 DOI: 10.1016/S0898-6568(01)00271-6]
50. Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 1994; 5: 261-268 [PMID: 7803762]
51. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERKinduced cell death- apoptosis, autophagy and senescence. FEBS J 2010; 277: 2-21 [PMID: 19843174 DOI: 10.1111/j.1742-4658.20 09.07366.x]
52. Chen A, Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005; 288: G447-G456 [PMID: 15486348 DOI: 10.1152/ajpgi.0020 9.2004]
53. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278-287 [PMID: 16170359 DOI: 10.1038/sj.onc.1209019]
54. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, Majumdar AP. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011; 28: 827-838 [PMID: 21161336 DOI: 10.1007/s11095-010-0336-y]
55. Chabner B, Barnes J, Neal J, Olson E, Mujagic H, Sequist L, Wilson W, Longo D, Mitsiades C, Richardson P. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2011
56. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318 [PMID: 9815926]
57. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311 [PMID: 15837620 DOI: 10.1016/j.ccr.2005.03.003]
58. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-1561 [PMID: 17332301 DOI: 10.1158/1078-0 432.CCR-06-1726]
59. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault- Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995 [PMID: 16618717 DOI: 10.1158/0008-5472. CAN-06-0191]
60. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515 [PMID: 17998284 DOI: 10.1093/annonc/mdm496]
61. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]
62. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]
63. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577 [PMID: 22734028 DOI: 10.1200/ JCO.2012.42.2592]
64. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with nonsmall- cell lung cancer. J Clin Oncol 2008; 26: 4244-4252 [PMID: 18779611 DOI: 10.1200/JCO.2007.15.0185]
65. Santoro A, Comandone A, Rimassa L, Granetti C, Lorusso V, Oliva C, Ronzoni M, Siena S, Zuradelli M, Mari E, Pressiani T, Carnaghi C. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 1888-1893 [PMID: 18667394 DOI: 10.1093/annonc/mdn401]
66. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957 [PMID: 19692680 DOI: 10.1056/NEJMoa0810699]
67. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388 [PMID: 20573926 DOI: 10.1056/NEJMoa0909530]
68. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 2012; 30: 1505-1512 [PMID: 22412142 DOI: 10.1200/ JCO.2011.38.6599]
69. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169 [PMID: 17375050 DOI: 10.1038/sj.bjc.6603685]
70. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712 [PMID: 19001320 DOI: 10.1200/ JCO.2008.18.0786]
71. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80: 199-211 [PMID: 7834740 DOI: 10.1016/0092-8674(95)90403-4]
72. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000; 19: 5429-5439 [PMID: 11032810 DOI: 10.1093/ emboj/19.20.5429]
73. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999; 19: 5308-5315 [PMID: 10409722]
74. Wangefjord S, Sundström M, Zendehrokh N, Lindquist KE, Nodin B, Jirström K, Eberhard J. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ 2013; 4: 17 [PMID: 24020794 DOI: 10.1186/2042-6410-4-17]
75. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86 [PMID: 21900593 DOI: 10.1126/scitranslmed.3002442]
76. Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011; 10: 325-332 [PMID: 21729677 DOI: 10.1016/j.clcc.2011.03.028]
77. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 1992; 7: 181-185 [PMID: 1741162]